KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

AbbVie (ABBV) Long-Term Debt Issuances (2016 - 2025)

AbbVie (ABBV) has disclosed Long-Term Debt Issuances for 7 consecutive years, with $4.0 billion as the latest value for Q1 2025.

  • On a quarterly basis, Long-Term Debt Issuances fell 73.31% to $4.0 billion in Q1 2025 year-over-year; TTM through Dec 2025 was $4.0 billion, a 76.45% decrease, with the full-year FY2025 number at $4.0 billion, down 76.45% from a year prior.
  • Long-Term Debt Issuances was $4.0 billion for Q1 2025 at AbbVie, up from $2.0 billion in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $15.0 billion in Q1 2024 to a low of $1.0 billion in Q3 2021.
  • A 4-year average of $4.8 billion and a median of $2.0 billion in 2022 define the central range for Long-Term Debt Issuances.
  • Biggest YoY gain for Long-Term Debt Issuances was 73.31% in 2025; the steepest drop was 73.31% in 2025.
  • AbbVie's Long-Term Debt Issuances stood at $1.0 billion in 2021, then surged by 100.0% to $2.0 billion in 2022, then changed by 0.0% to $2.0 billion in 2024, then skyrocketed by 99.7% to $4.0 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Long-Term Debt Issuances are $4.0 billion (Q1 2025), $2.0 billion (Q4 2024), and $15.0 billion (Q1 2024).